Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses recent findings from studies he participated in on targeted therapies for muscle-invasive bladder cancer.
Mike Lattanzi, MD, genitourinary medical oncologist at Texas Oncology, participated in 2 recent studies on bladder cancer.
You were a coauthor on a paper published last year on treating patients with Tecentriq and chemotherapy before surgery in muscle-invasive bladder cancer. Can you discuss these findings?
I was fortunate enough to be part of a large group effort of an investigator-initiated trial led by Sam Funt[, MD, urologic oncologist] and Jonathan Rosenberg[, MD, chief of the Genitourinary Oncology Service] at Memorial Sloan Kettering Cancer Center using combination platinum-based chemotherapy with gemciatbine and cisplatin with the addition of the PD-L1 antibody and atezolizumab for patients with muscle invasive urothelial cancer.
The study was a positive trial and hit the primary end point of pathologic downstaging, which we achieved in over half of patients. And we look further to additional combinations of immunotherapy in the neoadjuvant setting.
You've also explored the impact of human epidermal growth factor recepter (HER) alterations in bladder cancer. What are the treatment options in this area?
Bladder cancer actually has the highest rate of all HER2 alterations among the solid tumors. That includes, of course, both driver mutations, as well as genomic amplification. And there's increasing interest in the use of novel HER2-targeting antibody-drug conjugates for this subset of patients.
However, further work remains to be done to identify the optimal biomarker to select patients for benefit from these novel her to antibody-drug conjugates. And it's not clear at this time, if IHC [immunohistochemistry] is the optimal biomarker, or if we should be looking at other things like amplification or mutation.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More